Sitagliptin is the DPP-4 inhibitor whose dedicated cardiovascular outcomes trial, TECOS, kept it off the FDA's 2016 heart-failure warning that named saxagliptin and alogliptin instead.

Sitagliptin was studied in TECOS, a dedicated outcomes trial in nearly 14,700 patients with type 2 diabetes and established cardiovascular disease, published in the New England Journal of Medicine in 2015. It found no increase in major cardiovascular events or heart-failure hospitalization. When the FDA reviewed heart-failure signals from saxagliptin and alogliptin trials in 2016 and added warnings to those labels, sitagliptin was not included.

No. M Care Exports is a merchant-exporter, not a manufacturer, and does not hold WHO-GMP or WHO-PQ certification in its own name. Sitagliptin lines are sourced from Indian manufacturers that hold WHO-GMP certification for their own facilities. M Care's own certifications are ISO 9001:2015 for quality management and a CDSCO export licence. Manufacturing-site GMP documentation is provided on request to support the buyer's registration file.

Sitagliptin is marketed as film-coated oral tablets in 25mg, 50mg and 100mg strengths, and as fixed-dose combinations with metformin under the Janumet brand family. M Care can source branded reference product or generic sitagliptin, in tablet strengths matching the approved label, and combination lines where a buyer's registration calls for them. Availability of a specific strength, brand or generic line is confirmed against the buyer's purchase order at enquiry.

Sitagliptin's own hypoglycaemic potential is low, but combining it with insulin or a sulfonylurea increases hypoglycaemia risk, which the approved label flags as a class-effect caution requiring dose review of the companion agent. This is a clinical and formulary question for the buyer's own prescribing protocol; M Care does not provide patient dosing advice and defers to the destination-market approved label.

Yes. The approved label carries a caution for acute pancreatitis, including rare postmarketing reports of haemorrhagic or necrotising pancreatitis, and instructs prompt discontinuation if pancreatitis is suspected. Sitagliptin has not been specifically studied in patients with a prior history of pancreatitis. This is disclosed here because a buyer's regulatory and pharmacovigilance file should reflect it, not because M Care is advising on patient management.

Yes. Sitagliptin is predominantly cleared renally, and the approved label sets fixed dose reductions by estimated glomerular filtration rate (eGFR) band, down to the lowest strength in severe renal impairment or dialysis, rather than a titration schedule. This differs from oral antidiabetics whose dosing is adjusted for glycaemic response. Buyers should confirm the destination label reflects the same renal dosing bands before registration.

M Care supplies regulatory affairs teams, hospital procurement desks and licensed importers across the UK and EU, Gulf and GCC states, Africa, Latin America, Southeast Asia and CIS markets. India is the country of manufacture only; M Care does not sell into the Indian domestic market. Export terms and documentation are confirmed per shipment based on the buyer's destination and registration requirements.

DPP-4 inhibitors as a class, including sitagliptin, carry a labelled postmarketing signal for bullous pemphigoid, a blistering skin condition that typically resolves with discontinuation and immunosuppressive treatment. The approved label instructs discontinuing sitagliptin if bullous pemphigoid is suspected. Epidemiological studies show the signal is not uniform across the class; this is documentation context for a buyer's pharmacovigilance file, not treatment advice.